US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Ankylosing Spondylitis Market Size, Share & Trends Analysis Report By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia, Others)The Global The Global Ankylosing Spondylitis market size was valued at USD $3.32 Billion in 2020, USD $3.56 Billion in 2021, forecasted to reach USD $3.82 Billion in 2022, and is projected to reach USD $6.66 Billion by 2030, and is anticipated to expand at a CAGR of 7.2% over the forecast period from 2020 to 2030. Global Ankylosing Spondylitis Market is the title of an upcoming report offered by Trusted Business Insights. The report contains information and data, and inputs from both primary and secondary data sources, that have been verified and validated by experts in the target market. The report presents a thorough study of revenues, historical data, and information, key developments, and strategies by major players that offer vital insights and perspectives in various scenarios market. Besides critical data and related information, the report includes key trends (both present and future), factors that are driving market growth, factors that are or could be potential restraints to market growth, as well as opportunities that can be leveraged for potential revenue generation in untapped regions and countries. It also covers threats or challenges for existing as well as new entrants in the market. The global ankylosing spondylitis market has been segmented on the basis of drug outlook, as well as regions and countries.Request Covid - 19 Impact
Overview:Ankylosing spondylitis is an inflammatory disease that, over time, can cause some of the smaller bones in your spine to fuse. This fusing makes the spine less flexible and can result in a hunched-forward posture. Pain the back and joints are also common.
Dynamics:The entry of biosimilars, as well as the introduction and commercialization of novel products and increasing collaborations between industry players is expected to accelerate revenue growth of the global ankylosing spondylitis market over the next 10 years. Continual research & development efforts being undertaken by key industry players to augment treatment options is also anticipated to significantly impact the revenue growth of this global market in the years to come. However, in light of the recent COVID-19 pandemic, a majority of businesses have temporarily halted their operations, especially those that deal in the R&D, production and supply sectors. This factor is expected to play a considerably negative role in the revenue growth of the global ankylosing spondylitis market in the coming years.
Segmentation of the global ankylosing spondylitis market is as follows:In terms of drug insights, Humera accounted for the majority revenue share of the global ankylosing spondylitis market in 2019, owing to its high efficacy and low cost. Alternatively, Cosentyx is expected to become the fastest growing segment of the global ankylosing spondylitis market in the foreseeable future.
Regional Segmentation and Analysis:North America accounted for the majority revenue share of the global ankylosing spondylitis market in 2019, owing to the high prevalence of diseases in this region, and the commercial sales of branded drugs.
Below are the leading companies profiled in this Ankylosing Spondylitis Market Report:
Chapter 1 Methodology and Scope